Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)

40.81
Delayed Data
As of 4:14pm ET
 +0.52 / +1.30%
Today’s Change
31.38
Today|||52-Week Range
102.51
-56.65%
Year-to-Date
2 Reasons Why Alnylam Pharmaceuticals Stock Gained 18.5% in November
Dec 07 / MotleyFool.com - Paid Partner Content
7 of the Most Shocking Biotech Pipeline Blowups of 2016
Dec 04 / MotleyFool.com - Paid Partner Content
Alnylam Reports Positive Data on Fitusiran, Givosiran
Dec 05 / Zacks.com - Paid Partner Content
3 Things You Need to Know About Ionis Pharmaceuticals' Pipeline
Dec 01 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close40.28
Today’s open40.16
Day’s range39.28 - 40.99
Volume1,592,148
Average volume (3 months)1,342,496
Market cap$3.5B
Dividend yield--
Data as of 4:14pm ET, 12/08/2016

Growth & Valuation

Earnings growth (last year)+28.87%
Earnings growth (this year)-39.99%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)-18.72%
P/E ratioNM
Price/Sales192.40
Price/Book2.71

Competitors

 Today’s
change
Today’s
% change
ENDPEndo International P...+0.56+3.71%
AGNPRAAllergan plc-4.61-0.66%
ACADACADIA Pharmaceutica...+0.16+0.59%
GRFSGrifols SA+0.18+1.24%
Data as of 4:02pm ET, 12/08/2016

Financials

Next reporting dateFebruary 16, 2017
EPS forecast (this quarter)-$1.32
Annual revenue (last year)$41.1M
Annual profit (last year)-$290.1M
Net profit margin-705.83%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
John M. Maraganore
President
Barry E. Greene
Corporate headquarters
Cambridge, Massachusetts

Forecasts


Search for Jobs